Ireland: Healthcare

The Council of the EU has adopted the most comprehensive reform of EU pharmaceutical legislation in over 20 years, fundamentally reshaping regulatory protection mechanisms, market exclusivity periods, and incentive structures for pharmaceutical companies. These reforms balance patient access to medicines with creating a more competitive and innovation-friendly environment, addressing antimicrobial resistance, medicine supply challenges, and the early availability of generic alternatives.

The Health (Amendment) (Home Support Providers) Act 2026 (Act) was signed into law by the President on 1 July 2026. Although enacted, the Act has not yet been commenced, and will come into operation on dates appointed...

The European Commission's December 2025 Health Package proposes significant amendments to the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), responding to persistent industry calls for reform.

As part of the EU's Data Strategy, the European Health Data Space Regulation is intended to bring about greater reuse of electronic health data for research, innovation and policy-making purposes.

This week's package of health sector-focused measures from the European Commission contains a number of flagship deliverables under the July 2025 EU Life Sciences Strategy...

A blueprint for transforming Ireland's clinical trials landscape is set out in the Final Report and Recommendations of the National Clinical Trials Oversight Group (NCTOG), published on 21 November 2025.

The healthcare and life sciences landscape is constantly evolving as organisations strive to harness rapid technological advances.

Organisations across all sectors have, by and large, acquired a familiarity with the General Data Protection Regulation and have built compliance frameworks for the processing of personal data...

We talk to Oliver O'Connor, CEO, Irish Pharmaceutical Healthcare Association, about his role, his career journey and his views on some key issues faced by the industry.